Pancreatic cancer progress is being driven by three main areas: prevention, new treatment technology, and artificial intelligence. Because there is no standard screening for the general public, prevention focuses on quitting smoking, maintaining a healthy weight, and monitoring family history. Doctors also encourage genetic testing for high-risk individuals and are studying the link between high blood sugar and early-stage disease.
A new treatment option is Optune Pax, recently approved by the FDA for locally advanced pancreatic cancer. The wearable device uses Tumor Treating Fields—electrical pulses that disrupt cancer cell division. It targets the tumor directly and may cause fewer whole-body side effects than traditional chemotherapy.
Artificial intelligence is also improving treatment decisions. An AI tool developed by Valar Labs analyzes pathology slides to predict whether a patient will respond better to FOLFIRINOX or gemcitabine. This approach helps doctors choose the most effective chemotherapy from the start, saving time and reducing unnecessary side effects. Researchers are also exploring liquid biopsies, AI-enhanced imaging, and large-scale data sharing to detect pancreatic cancer earlier and improve access to care.